Study guide

5.2 Cytochrome P450 Systems & High-Risk Drug Interactions

MRCP UK

Track your progress as you read

Finished sections get a check mark.

1 MRCP(UK) Part 1: Exam Overview, Blueprint & Strategy

1.1 Part 1 Format, Delivery and Fees 1.2 The Official Blueprint and Mark Allocation 1.3 Scaled Scoring, Attempt Limits and Best-of-Five Technique

2 Clinical Sciences: Cellular, Genetic & Molecular Medicine

2.1 Organelles, Cytoskeleton & Membrane Transport 2.2 Cell Cycle Control, Apoptosis & Cell Signalling 2.3 Mendelian & Non-Mendelian Inheritance 2.4 Trinucleotide Repeat Disorders & Chromosomal Abnormalities 2.5 Purine, Pyrimidine Metabolism & the Porphyrias 2.6 Glycogen, Lipid Storage & Amino Acid Disorders

3 Clinical Sciences: Anatomy, Physiology & Immunology

3.1 Clinical & Cross-Sectional Anatomy 3.2 Systemic Clinical Physiology & Homeostasis 3.3 Clinical Immunology & Hypersensitivity Reactions

4 Clinical Sciences: Statistics, Epidemiology & Trial Design

4.1 Study Designs & Evidence Hierarchy 4.2 Diagnostic Testing, Screening & Predictive Values 4.3 Statistical Analysis & Risk Quantification

5 Clinical Pharmacology, Therapeutics & Toxicology

5.1 Pharmacokinetics & Pharmacodynamics 5.2 Cytochrome P450 Systems & High-Risk Drug Interactions 5.3 Adverse Drug Reactions & Therapeutic Drug Monitoring 5.4 Paracetamol & Salicylate Poisoning 5.5 Toxidromes, Antidotes, Carbon Monoxide & Toxic Alcohols

6 Cardiology: Coronary Artery Disease & Heart Failure

6.1 Acute Coronary Syndromes & Myocardial Infarction 6.2 Heart Failure & Cardiomyopathies 6.3 Cardiac Assessment & ECG Interpretation

7 Cardiology: Arrhythmias, Valvular & Pericardial Disease

7.1 Atrial Fibrillation, Narrow & Broad Complex Tachycardias 7.2 Bradyarrhythmias, Conduction Block & Antiarrhythmic Drugs 7.3 Valvular Heart Disease & Murmur Interpretation 7.4 Infective Endocarditis 7.5 Pericardial & Acute Aortic Diseases

8 Respiratory Medicine: Airway & Parenchymal Lung Disease

8.1 Asthma: Diagnosis, Chronic Management & Acute Attacks 8.2 COPD: GOLD Staging, Stable Management, Exacerbations & NIV 8.3 Interstitial Lung Disease & Sarcoidosis 8.4 Respiratory Infections & Bronchiectasis

9 Respiratory Medicine: Vascular, Pleural & Sleep Disorders

9.1 Venous Thromboembolism & Pulmonary Embolism 9.2 Pleural Effusion & Pneumothorax 9.3 Respiratory Failure & Sleep-Disordered Breathing

10 Gastroenterology: Luminal Gastrointestinal Disease

10.1 GORD, Barrett's Oesophagus & Oesophageal Motility Disorders 10.2 Peptic Ulcer Disease, Helicobacter pylori & Zollinger-Ellison Syndrome 10.3 Crohn's Disease, Ulcerative Colitis & Extraintestinal Manifestations 10.4 IBD Medical Therapy, Coeliac Disease & Malabsorption 10.5 Acute Upper Gastrointestinal Bleeding: Risk Scores, Ulcer & Variceal Haemorrhage 10.6 Lower Gastrointestinal Disorders & Colonic Neoplasia

11 Gastroenterology: Liver, Biliary & Pancreatic Disease

11.1 Viral Hepatitis A to E 11.2 Autoimmune Hepatitis & Metabolic Liver Disease 11.3 Cirrhosis & Complications of Portal Hypertension 11.4 Cholestatic Liver Disease: PBC and PSC 11.5 Gallstone Disease, Biliary Sepsis & Pancreatitis

12 Endocrinology & Diabetes: Diabetes & Thyroid

12.1 Diabetes: Diagnostic Thresholds, Classification & Pathophysiology 12.2 NICE-Directed Type 2 Therapy & Microvascular Complications 12.3 Acute Diabetic Emergencies (DKA & HHS) 12.4 Thyrotoxicosis, Thyroiditis & Management of Hyperthyroidism 12.5 Hypothyroidism, Subclinical Disease & Thyroid Nodules

13 Endocrinology & Diabetes: Adrenal, Pituitary & Calcium

13.1 Hypopituitarism, Pituitary Apoplexy & Hyperprolactinaemia 13.2 Acromegaly, Diabetes Insipidus & SIADH 13.3 Cushing's Syndrome: Aetiology, Screening & Localisation 13.4 Adrenal Insufficiency & Endocrine Hypertension 13.5 Calcium Regulation & Hypercalcaemia 13.6 Hypocalcaemia & Metabolic Bone Disease

14 Renal Medicine: AKI, Glomerular & Tubulointerstitial Disease

14.1 Acute Kidney Injury & Chronic Kidney Disease 14.2 Nephrotic and Nephritic Syndromes & Primary Glomerular Disease 14.3 Rapidly Progressive Glomerulonephritis 14.4 Tubulointerstitial & Inherited Renal Diseases

15 Renal Medicine: Fluid, Electrolytes & Acid-Base Balance

15.1 Sodium & Water Disorders 15.2 Potassium, Magnesium & Phosphate Disorders 15.3 Acid-Base Disorders & Blood Gas Analysis

16 Neurology: Cerebrovascular, Headache & Demyelinating Disease

16.1 Stroke Classification, Brainstem Syndromes & Hyperacute Reperfusion 16.2 Secondary Prevention, TIA, Carotid Surgery & Intracranial Haemorrhage 16.3 Headache Disorders & Cranial Neuralgias 16.4 Multiple Sclerosis & Central Demyelinating Diseases

17 Neurology: Epilepsy, Movement Disorders & Neuromuscular Disease

17.1 Epilepsy & Acute Seizures 17.2 Movement Disorders & Cognitive Impairment 17.3 Neuromuscular Junction & Peripheral Nerve Disorders

18 Rheumatology: Inflammatory Arthritis & Connective Tissue Disease

18.1 Rheumatoid Arthritis: Pathophysiology, Clinical Features & Diagnosis 18.2 DMARDs, Biologics & Their Toxicities 18.3 Seronegative Spondyloarthropathies 18.4 Systemic Lupus Erythematosus & Drug-Induced Lupus 18.5 Systemic Sclerosis & Scleroderma Renal Crisis 18.6 Sjogren's Syndrome & Inflammatory Myopathies

19 Rheumatology: Systemic Vasculitis & Crystal Arthropathy

19.1 Vasculitis Classification, Large and Medium Vessel Disease 19.2 ANCA-Associated and Immune Complex Small Vessel Vasculitis 19.3 Gout & Calcium Pyrophosphate Deposition Disease

20 Infectious Diseases & Tropical Medicine

20.1 Sepsis-3 Definitions & the Sepsis Six 20.2 Bacterial Meningitis, CSF Interpretation & Toxic Shock Syndrome 20.3 Tuberculosis: Pathogenesis & Clinical Manifestations 20.4 Tuberculosis: Diagnosis & Anti-Tuberculous Therapy 20.5 HIV Infection & Opportunistic Diseases 20.6 Malaria: Species, Life Cycle & Severe Disease 20.7 Enteric Fever, Arboviral Infection & Tissue Parasites

21 Haematology: Anaemias & Red Cell Disorders

21.1 MCV-Based Diagnostic Approach to Anaemia 21.2 Haemolytic and Autoimmune Haemolytic Anaemias 21.3 Membranopathies, Enzymopathies, PNH & Sickle Cell Disease

22 Haematology: Malignancy, Coagulation & Transfusion Medicine

22.1 Acute Leukaemias 22.2 Chronic Leukaemias & Myeloproliferative Neoplasms 22.3 Lymphomas & Plasma Cell Dyscrasias 22.4 Coagulation Cascade & Inherited Bleeding Disorders 22.5 Thrombocytopenia & Thrombotic Microangiopathies 22.6 Transfusion Products & Acute Transfusion Reactions

23 Psychiatry in General Medicine

23.1 Mood & Psychotic Disorders in Medical Patients 23.2 Psychiatric Emergencies & Substance Misuse 23.3 Mental Capacity & UK Mental Health Law

24 Geriatric Medicine

24.1 Comprehensive Geriatric Assessment, Frailty, Delirium & Falls 24.2 Polypharmacy, Deprescribing & Pressure Ulcers

25 Dermatology

25.1 Inflammatory Skin Disease, Immunobullous Disorders & Severe Drug Eruptions 25.2 Cutaneous Malignancy

26 Oncology & Palliative Medicine

26.1 Neutropenic Sepsis, Spinal Cord Compression & SVC Obstruction 26.2 Hypercalcaemia of Malignancy & Tumour Lysis Syndrome 26.3 Palliative Care & End-of-Life Symptom Control

27 Medical Ophthalmology

27.1 The Acute Red Eye & Sudden Painless Visual Loss 27.2 Retinopathy in Systemic Disease

5.2 Cytochrome P450 Systems & High-Risk Drug Interactions

Key Takeaways Explain This Topic AI

Cytochrome P450 enzymes (haemoprotein monooxygenases) mediate Phase I functionalisation reactions (oxidation, reduction, hydrolysis), with CYP3A4, CYP2D6, CYP2C9, CYP2C19, and CYP1A2 responsible for metabolising > 90% of prescription drugs.

CYP2D6 exhibits marked pharmacogenomic polymorphism; poor metabolisers fail to convert prodrugs (codeine, tramadol) into active analgesics, whereas ultra-rapid metabolisers risk fatal opioid toxicity from therapeutic doses.

Potent enzyme inducers (rifampicin, carbamazepine, phenytoin, phenobarbital, St John's wort) upregulate CYP synthesis over 1–2 weeks, precipitating contraceptive failure, loss of warfarin/DOAC anticoagulation, or acute organ transplant rejection.

Potent enzyme inhibitors (clarithromycin, azole antifungals, ciprofloxacin, amiodarone, diltiazem, grapefruit juice) act immediately, causing dangerous drug accumulation, statin-induced rhabdomyolysis, supratherapeutic INR, or fatal colchicine toxicity.

Crucial non-CYP interactions include P-glycoprotein (MDR1) efflux modulation, methotrexate clearance inhibition by NSAIDs and trimethoprim, and synergistic hyperkalaemia from combining renin-angiotensin blockers with potassium-sparing diuretics or trimethoprim.

Last updated: September 2026

Note

Curriculum Focus : The MRCP(UK) Part 1 consistently tests mechanisms of adverse drug-drug interactions. Candidates are expected to identify the specific CYP isoenzyme responsible for metabolising key cardiovascular, neurological, and immunosuppressive agents, distinguish enzyme inducers from inhibitors, understand the timeline of enzyme modulation, and anticipate critical non-CYP pharmacokinetic interactions.

Hepatic drug metabolism transforms lipophilic xenobiotics into polar, water-soluble metabolites suitable for renal or biliary elimination. This biotransformation occurs in two consecutive phases:

Phase I Reactions (Functionalisation) : Introduce or unmask polar functional groups (-OH, -NH2, -SH, -COOH) via oxidation, reduction, or hydrolysis . Predominantly catalysed by the Cytochrome P450 (CYP450) superfamily of haemoprotein monooxygenases embedded in the smooth endoplasmic reticulum.

Phase II Reactions (Conjugation) : Covalently couple the drug or Phase I metabolite with an endogenous hydrophilic molecule via glucuronidation (UGT), sulfation (SULT), glutathione conjugation (GST), or acetylation (NAT) . Phase II reactions are generally preserved longer than Phase I oxidations in patients with advancing liver cirrhosis.

Overview of Critical CYP Isoforms and Pharmacogenomics

Although dozens of CYP isoforms exist, five distinct isoenzymes handle over 90% of clinically significant drug biotransformations: +-----------------------------------------------------------------------------------------+

  • | Major Cytochrome P450 Isoforms |
  • +-----------------------------------------------------------------------------------------+
  • | CYP3A4 • Abundance: ~30% of hepatic CYP; metabolises > 50% of prescription drugs |
  • | • Substrates: Statins, Calcineurin inhibitors, DOACs, Calcium blockers |
  • | |
  • | CYP2D6 • Abundance: ~2% of hepatic CYP; metabolises ~25% of prescription drugs |
  • | • Highly polymorphic: Poor vs Ultra-Rapid metabolisers (codeine, tamoxifen) |
  • | |
  • | CYP2C9 • Key Substrates: S-warfarin (active), Phenytoin, Sulfonylureas, NSAIDs |
  • | |
  • | CYP2C19 • Key Substrates: Clopidogrel bioactivation, Omeprazole, Diazepam |
  • | |
  • | CYP1A2 • Key Substrates: Theophylline, Clozapine; strongly induced by cigarette smoke |
  • +-----------------------------------------------------------------------------------------+
  • 1. CYP3A4: The Dominant Metabolic Engine

CYP3A4 is the most abundant isoform in both the liver and the intestinal epithelium. It exhibits broad substrate specificity, rendering it exceptionally vulnerable to competitive inhibition and transcriptional upregulation.

High-Risk Substrates : Statins (simvastatin, atorvastatin; notably not pravastatin or rosuvastatin), calcineurin inhibitors (tacrolimus, ciclosporin), direct oral anticoagulants (rivaroxaban, apixaban), dihydropyridine calcium channel blockers, phosphodiesterase-5 inhibitors (sildenafil), and oral midazolam.

2. CYP2D6: Pharmacogenomic Polymorphisms and Prodrug Activation

CYP2D6 is genetically non-inducible but exhibits profound genetic polymorphism governed by autosomal recessive alleles and gene duplication events:

Poor Metabolisers (5–10% of Caucasians) : Possess inactive CYP2D6 alleles (*4, *5). They cannot activate prodrugs that depend on CYP2D6 cleavage:

Codeine & Tramadol : Codeine is an inactive prodrug requiring CYP2D6 O-demethylation into morphine to produce analgesia. Poor metabolisers experience zero pain relief.

Tamoxifen : Requires CYP2D6 conversion to its 100-fold more active anti-oestrogenic metabolite, endoxifen . Poor metabolisers (or women co-prescribed potent CYP2D6 inhibitors like fluoxetine or paroxetine) experience significantly higher rates of breast cancer recurrence.

Ultra-Rapid Metabolisers (up to 20–30% of North/East African populations) : Possess multiple functional gene copies (up to 13 copies). Therapeutic doses of codeine produce rapid, massive generation of free morphine, resulting in life-threatening respiratory depression, coma, and neonatal fatalities via breast milk.

3. CYP2C9: S-Warfarin and Narrow Therapeutic Index Drugs

Warfarin is administered as a racemic mixture of R- and S-enantiomers. The S-enantiomer is 3- to 5-times more potent than the R-enantiomer and is cleared exclusively by CYP2C9 . Polymorphic variants (CYP2C9 2 and CYP2C9 3) exhibit impaired clearance, predisposing patients to catastrophic haemorrhage on standard induction doses.

4. CYP2C19: Clopidogrel Bioactivation

Clopidogrel is an inactive thienopyridine prodrug that requires a two-step hepatic oxidation, heavily reliant on CYP2C19 , to generate its active thiol platelet-inhibitor metabolite. Concomitant use of omeprazole (a potent CYP2C19 inhibitor) blunts clopidogrel antiplatelet efficacy, increasing stent thrombosis rates. In contrast, pantoprazole exhibits minimal CYP2C19 inhibition and is the proton-pump inhibitor of choice in patients receiving dual antiplatelet therapy.

5. CYP1A2: Cigarette Smoke Interactions

CYP1A2 metabolises theophylline, caffeine, clozapine, and olanzapine. The polycyclic aromatic hydrocarbons present in cigarette smoke (not nicotine itself) potently induce CYP1A2. When a psychiatric patient stabilised on clozapine abruptly ceases smoking upon hospital admission, CYP1A2 de-induces, precipitating severe clozapine toxicity (sedation, seizures, agranulocytosis).

High-Yield Matrix: Potent CYP Inducers vs Inhibitors

Understanding the biochemical timeline is clinically crucial: inhibition occurs immediately (within hours) as the inhibitor competes for the enzyme catalytic site; induction requires 7–14 days to manifest because it requires nuclear receptor transcription (PXR, CAR) and de novo enzyme protein synthesis, and persists for 1–3 weeks following drug discontinuation.

CYP Modulator Category Mnemonic & Key Agents Primary Isoforms Affected Major Clinical Consequences

Potent Inducers "CRAP GPS" ; • C arbamazepine; • R ifampicin; • A lcohol (chronic); • P henytoin; • G riseofulvin; • P henobarbital; • S t John's Wort; • Tobacco Smoke (CYP1A2) CYP3A4; CYP2C9; CYP1A2; P-glycoprotein • Contraceptive Failure : Combined pills, progestogen-only pills, and implants fail; copper IUD or Depo-Provera injection required.; • Thromboembolism : Rapid decline in warfarin INR and subtherapeutic DOAC levels.; • Graft Rejection : Catastrophic subtherapeutic tacrolimus/ciclosporin levels.

Potent Inhibitors "SICKFACES.COM" ; • S odium Valproate; • I soniazid; • C imetidine; • K etoconazole / Azoles; • F luconazole; • A lcohol (acute binge); • C hloramphenicol; • E rythromycin / Clarithromycin; • S ulfonamides (Cotrimoxazole); • C iprofloxacin; • O meprazole; • M etronidazole; • Amiodarone, Diltiazem, Verapamil, Ritonavir, Grapefruit Juice CYP3A4; CYP2C9; CYP1A2; CYP2D6; P-glycoprotein • Statin Rhabdomyolysis : Clarithromycin or itraconazole co-prescribed with simvastatin/atorvastatin causes severe myopathy and AKI.; • Fatal Haemorrhage : Supratherapeutic warfarin INR with metronidazole, cotrimoxazole, or amiodarone.; • Calcineurin Toxicity : Acute renal failure and neurotoxicity from tacrolimus with azoles or macrolides.; • Colchicine Toxicity : Fatal marrow aplasia when combined with clarithromycin.

Warning

Grapefruit Juice & Intestinal CYP3A4 :

Grapefruit juice contains furanocoumarins (e.g., bergamottin) that selectively and irreversibly destroy enterocyte (intestinal wall) CYP3A4 via suicide inhibition, without affecting hepatic CYP3A4. This selectively annihilates the oral first-pass extraction of substrates, increasing simvastatin bioavailability up to 15-fold and causing fulminant rhabdomyolysis.

Critical Non-CYP Pharmacokinetic & Pharmacodynamic Interactions

Beyond the CYP450 superfamily, the MRCP Part 1 frequently tests three life-threatening non-CYP interaction mechanisms:

1. P-Glycoprotein (MDR1 / ABCB1) Transporter Interactions

P-glycoprotein is an ATP-dependent efflux pump located on the apical membranes of enterocytes (pumps drug back into intestinal lumen), renal proximal tubular cells (pumps drug into urine), biliary canaliculi (pumps into bile), and brain capillary endothelial cells (blood-brain barrier defense).

P-gp Substrates : Digoxin , dabigatran etexilate, rivaroxaban, ciclosporin, loperamide.

P-gp Inhibitors : Amiodarone, Verapamil, Clarithromycin, Quinidine, Diltiazem .

Clinical Disaster : Adding amiodarone or verapamil to a stable digoxin regimen inhibits renal and intestinal P-gp excretion, doubling serum digoxin concentrations and precipitating complete heart block. When starting amiodarone, the digoxin dose must immediately be halved by 50% .

2. Methotrexate and Organic Anion Transporter (OAT) Competition

Methotrexate is cleared predominantly by active renal proximal tubular secretion mediated by Organic Anion Transporters 1 and 3 (OAT1/OAT3) .

Interacting Drugs : NSAIDs (ibuprofen, naproxen), Penicillins (piperacillin-tazobactam, amoxicillin), and Proton Pump Inhibitors compete directly for OAT binding sites, dramatically reducing methotrexate clearance.

Cotrimoxazole (Trimethoprim-Sulfamethoxazole) : Possesses a lethal dual interaction with methotrexate: sulfamethoxazole displaces methotrexate from albumin, and trimethoprim inhibits both renal tubular excretion and acts as a synergistic inhibitor of dihydrofolate reductase (DHFR). This combination induces fulminant bone marrow aplasia (pancytopenia), mucositis, and sepsis . +------------------------------------------------------------------------------------------+

  • | Methotrexate & Cotrimoxazole Dual Toxicity |
  • +------------------------------------------------------------------------------------------+
  • | [Sulfamethoxazole] -------> Displaces Methotrexate from Albumin |
  • | | |
  • | [Trimethoprim] -----------> Blocks Renal OAT1/OAT3 Secretion |
  • | v |
  • | Massive Surge in Free Methotrexate |
  • | + |
  • | [Trimethoprim] -----------> Synergistic Dihydrofolate Reductase (DHFR) Blockade |
  • | v |
  • | Pancytopenia & Bone Marrow Aplasia |
  • +------------------------------------------------------------------------------------------+
  • 3. Synergistic Hyperkalaemia Pathways

Potassium homeostasis is exquisitely sensitive to multi-drug regimens affecting the distal nephron:

The Triad : Combining ACE inhibitors / ARBs (diminish aldosterone secretion) with Potassium-sparing diuretics (spironolactone, eplerenone, amiloride) and Trimethoprim .

Trimethoprim Mechanism : Trimethoprim has a chemical structure closely resembling the potassium-sparing diuretic amiloride. It competitively blocks the epithelial sodium channel (ENaC) in the apical membrane of the renal collecting tubule, eliminating the lumen-negative transepithelial potential required for potassium excretion. Co-prescribing trimethoprim with spironolactone or ramipril routinely precipitates emergency refractory hyperkalaemia (K+ > 7.0 mmol/L) and fatal ventricular arrhythmias.

Loading diagram... Renal Distal Nephron Interactions Causing Fatal Hyperkalaemia